![conference banner](/images/conference-banner.jpeg)
Abstract
Alzheimers disease (AD) is a progressive neurodegenerative disorder. To date, there is no cure for this disease. The FDA approved drugs, cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine) and an N-methyl-Daspartate receptor antagonist (memantine) for the treatment of AD are symptomatically effective to some patients for short periods of time. Cholinesterase inhibitors exert additional pharmacological action beyond inhibition of cholinesterase that may maximize and prolong the effective of these drugs. The complexity of AD pathogenesis limits these drugs to correct every aspect of the disease. This problem has led to the current challenge in drug discovery to develop multitarget or combinational therapy. EGb 761 is a standardized extract of Ginkgo biloba leaves and has been shown to have potential benefit effects in various models of AD. Combination drug therapy, the use of drugs that act at different targets, may offer a novel strategy for management of AD. In this review, we evaluate mechanisms of individual drugs for treatment of AD and summarize the combination studies between cholinesterase inhibitors and NMDA receptor antagonist memantine, cholinesterase inhibitors and EGb 761 in experimental models and clinical trials.
Keywords: Alzheimer's disease, combination therapy, Ginkgo biloba
Central Nervous System Agents in Medicinal Chemistry
Title: Mechanism of CNS Drugs and their Combinations for Alzheimers Disease
Volume: 8 Issue: 4
Author(s): Roongpetch Keowkase and Yuan Luo
Affiliation:
Keywords: Alzheimer's disease, combination therapy, Ginkgo biloba
Abstract: Alzheimers disease (AD) is a progressive neurodegenerative disorder. To date, there is no cure for this disease. The FDA approved drugs, cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine) and an N-methyl-Daspartate receptor antagonist (memantine) for the treatment of AD are symptomatically effective to some patients for short periods of time. Cholinesterase inhibitors exert additional pharmacological action beyond inhibition of cholinesterase that may maximize and prolong the effective of these drugs. The complexity of AD pathogenesis limits these drugs to correct every aspect of the disease. This problem has led to the current challenge in drug discovery to develop multitarget or combinational therapy. EGb 761 is a standardized extract of Ginkgo biloba leaves and has been shown to have potential benefit effects in various models of AD. Combination drug therapy, the use of drugs that act at different targets, may offer a novel strategy for management of AD. In this review, we evaluate mechanisms of individual drugs for treatment of AD and summarize the combination studies between cholinesterase inhibitors and NMDA receptor antagonist memantine, cholinesterase inhibitors and EGb 761 in experimental models and clinical trials.
Export Options
About this article
Cite this article as:
Keowkase Roongpetch and Luo Yuan, Mechanism of CNS Drugs and their Combinations for Alzheimers Disease, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (4) . https://dx.doi.org/10.2174/187152408786848166
DOI https://dx.doi.org/10.2174/187152408786848166 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Circular RNAs in Prostate Cancer
Current Medicinal Chemistry Interactions of Copper(II) and Zinc(II) Ions with the Peptide Fragments of Proteins Related to Neurodegenerative Disorders: Similarities and Differences
Current Medicinal Chemistry Emerging Pharmacological Properties of Cholinergic Synaptic Transmission: Comparison between Mammalian and Insect Synaptic and Extrasynaptic Nicotinic Receptors
Current Neuropharmacology State Dissociation, Human Behavior, and Consciousness
Current Topics in Medicinal Chemistry The Impact of Phytosterols on the Healthy and Diseased Brain
Current Medicinal Chemistry Omics-based Biomarkers for the Early Alzheimer Disease Diagnosis and Reliable Therapeutic Targets Development
Current Neuropharmacology Stem Cell Therapy for the Treatment of Parkinson's Disease: What Promise Does it Hold?
Current Stem Cell Research & Therapy Biomarkers in Hypertension and Hypertension-related Disorders
Current Medicinal Chemistry An Update on Human Stem Cell-Based Therapy in Parkinson's Disease
Current Stem Cell Research & Therapy Molecular Docking Studies of Methamphetamine and Amphetamine- Related Derivatives as an Inhibitor against Dopamine Receptor
Current Computer-Aided Drug Design Statins and the Brain: More than Lipid Lowering Agents?
Current Neuropharmacology Preface
Current Enzyme Inhibition In Vivo MRI in Different Models of Experimental Epilepsy
Current Drug Targets Anti-inflammatory Potential of GSK-3 Inhibitors
Current Drug Targets Therapeutic Approaches for Lysosomal Storage Diseases: A Patent Update
Recent Patents on CNS Drug Discovery (Discontinued) New Avenue of Research: Antiepileptic Drug and Estradiol Neuroprotection in Epilepsy
Recent Patents on CNS Drug Discovery (Discontinued) Ginsenoside Rg1 Attenuates Oligomeric Aβ1-42-Induced Mitochondrial Dysfunction
Current Alzheimer Research Modulation of Amyloid β Peptide1-42 Cytotoxicity and Aggregation in Vitro by Glucose and Chondroitin Sulfate
Current Alzheimer Research Liquid Filled Hard Shell Capsules: Current Drug Delivery Influencing Pharmaceutical Technology
Current Drug Delivery Therapeutic and Health Promoting Potential of <i>Terminalia chebula</i>: An Exploratory Literature Review
Current Traditional Medicine